Applicazioni cliniche dei farmaci antiangiogenetici
Download
1 / 33

APPLICAZIONI CLINICHE DEI FARMACI ANTIANGIOGENETICI - PowerPoint PPT Presentation


  • 287 Views
  • Uploaded on

APPLICAZIONI CLINICHE DEI FARMACI ANTIANGIOGENETICI. Giampaolo Tortora. Cattedra di Oncologia Medica UOC e Laboratori di Terapia molecolare dei tumori Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica Università di Napoli Federico II. Strategies to inhibit VEGF signalling.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' APPLICAZIONI CLINICHE DEI FARMACI ANTIANGIOGENETICI' - oro


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Applicazioni cliniche dei farmaci antiangiogenetici

APPLICAZIONI CLINICHE DEI FARMACI ANTIANGIOGENETICI

Giampaolo Tortora

Cattedra di Oncologia Medica

UOC e Laboratori di Terapia molecolare dei tumori

Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica

Università di Napoli Federico II


Strategies to inhibit VEGF signalling

Ferrara & Kerbel Nature 438: 967–974, 2005.



Bevacizumab
Bevacizumab

  • 93% human, 7% murine

  • Recognizes all isoforms of VEGF (Kd = 8x10–10M)

  • Terminal half-life 17–21 days

  • No DLT as single agent

  • inhibits all functions of the VEGF ligand:

    • on vascular endothelial cells

    • on non-endothelial cells (dendritic cells, monocytes)

VEGF isoforms recognised by hypervariable murine antibody fragment

Human IgG-1


Conseguenze della iperespressione e ipersecrezione di vegf
Conseguenze della iperespressione e ipersecrezione di VEGF

  • Migrazione e proliferazione endoteliale

  • Distorsione dell’architettura vascolare

  • Aumento della permeabilità vascolare e della PIF

  • Modulazione della risposta immune


Bevacizumab: effetti sulla vascolarizzazione tumorale

Bevacizumab

Normale

Normalizzata

Anormale

Riduce

la pressione del liquido interstiziale

e la densità microvascolare

Incrementa

il rilascio intratumorale dei farmaci

Modificato da Jain RK. Nat Med 2001; 7:987–9

Willett CG. et al. Nat Med 2004; 10:145–7

Tong R. et al. Cancer Res 2004; 64:3731–6$


Evidenza diretta degli effetti di Bevacizumab sulla vascolatura tumorale umana: studio fase I

Patienti con ca rettale primario e non metastatico

(n=6)

Avastin 5 mg/kg +5-FU i.c. + Radioterapia

Avastin 5 mg/kg

Chirurgia

2 settimane

3 volte ogni 2 settimane

  •  perfusione sanguigna tumorale(40–44%, p<0.05)

  •  volume sanguigno tumorale(16–39%, p<0.05)

  •  densità microvascolare(25–59%, p<0.05)

     pressione interstiziale

    (da 15.0 ± 2.0 a 4.0 ± 2.2 mm Hg, p<0.01)

Sangue/urine TAC funzionale/PET Endoscopia Biopsia tumorale

Willett CG, et al. Nat Med 2004;10:145–7


Avastin aumenta la sopravvivenza in diversi tumori vascolatura tumorale umana: studio fase I

Ca colorettale 1a linea (NEJM 2004)

Ca colorettale 2a linea (ASCO 2005)

Ca polmonare 1a linea (ASCO 2005)

Ca mammario 1a linea (ASCO 2005)


E3200 progression free survival
E3200: progression-free survival vascolatura tumorale umana: studio fase I

50% Incremento netto

Giantonio BJ, et al. J Clin Oncol 2005;23(June 1 Suppl.):1s (Abstract 2)


E3200 overall survival
E3200: overall survival vascolatura tumorale umana: studio fase I

Giantonio BJ, et al. J Clin Oncol 2005;23(June 1 Suppl.):1s (Abstract 2)


Planned trials in adjuvant colon cancer

Studio vascolatura tumorale umana: studio fase I

n

Tumore

Stadio

Trattamento

3450

Colon

BO17920

II (alto

FOLFOX4

vs

(Avant)

rischio) III

FOLFOX4 + Avastin

vs

XELOX + Avastin

NSABP C

-

08

2700

Colon

FOLFOX6 ± Avastin

II (alto

rischio) III

II (alto

E5205

3125

Colon

FOLFOX6 ± Avastin

rischio

QUAS

AR

-

2

1900

Colon

III

Xeloda ± Avastin

Planned trials in adjuvant colon cancer

>11.000


Binding del vegf ai recettori
Binding del VEGF ai recettori vascolatura tumorale umana: studio fase I

VEGFR-3/Flt-4

VEGFR-1/Flt-1

VEGFR-2/KDR

LYMPHANGIOGENESIS

ANGIOGENESIS


EGFR vascolatura tumorale umana: studio fase I

gefitinib (IRESSA™)

erlotinib (Tarceva™)

ZD6474

AEE788

VEGFR

ZD6474

vatalanib

AZD2171

SU11248

AEE788

sorafenib

Bcr-Abl

imatinib (Glivec™)

c-Kit

AZD2171

imatinib

SU11248

PDGFR

imatinib

SU11248

sorafenib

Key receptor tyrosine kinases and selective inhibitors


Agents affecting all VEGFRs vascolatura tumorale umana: studio fase I

  • AZD2171

  • LY317615 (Enzastaurin)

  • CEP7055

  • GW786024


Azd2171

AZD2171 vascolatura tumorale umana: studio fase I

VEGFR2 (KDR)

VEGFR1

(Flt-1)

VEGFR3

(Flt-4)

AZD2171

  • AZD2171 is an oral therapy with potential application in multiple tumor types

  • AZD2171 has activity against VEGF receptors 1, 2 & 3- No activity on EGFR

  • Phase I clinical studies in refractory solid tumors underway

  • Manageable toxicity in early phase I


GSK3 vascolatura tumorale umana: studio fase Ib

COX2

IP3/Ca2+

DAG

IL-8

AKT

IL-6

PKC-b and the Proposed Action of Enzastaurin on Angiogenesis and Apoptosis

Acyclic indolylmaleimide competing with the ATP binding site

VEGF

ENZASTAURIN

Receptor

  • Tumor invasion

  • Angiogenesis

Apoptosis

PKC-b

Caspase 9

Protein translation

Activation

mRNA


Combination of 2 selective inhibitors approach
Combination of 2 selective inhibitors approach vascolatura tumorale umana: studio fase I


Combined blockade of EGFR and VEGF vascolatura tumorale umana: studio fase I

Erlotinib

Cetuximab, etc

Bevacizumab etc.

EGFR

Endothelial cells

Cancer cells

VEGF

Angiogenesis

Cell Proliferation

Tortora et al. 2004


3 Phase II studies of Bevacizumab and Erlotinib in Patients with Renal Carcinoma (RCC), Breast cancer and NSCLC

  • RCC (59 pts.): 47% Responses (including MR) and 39% SD;

    76% 1 year Overall survival (Hainsworth et al., ASCO 2004; Spigel et al., ASCO 2005).

  • NSCLC: 85% Disease control (including 20% PR);

    52% 1 year Overall survival and 7 mo. PFS (Sandler et al., ASCO 2005).

  • Breast Cancer: 33% Disease control (including PR) in heavily pretreated patients. Early data (Rugo et al., ASCO 2005).

Hainsworth JD, et al. J Clin Oncol 2004;22(July 15 Suppl.): Abstract 4502

Sandler AB, et al. J Clin Oncol 2004;22(July 15 Suppl.) Abstract 2000

Rugo H et al., J Clin Oncol 2004;22(July 15 Suppl.)


Indirect Comparison of the Efficacy Results with Renal Carcinoma (RCC), Breast cancer and NSCLC

in BOND-1 and BOND-2

Modified from Saltz et al., ASCO 2005


Multitargeted agents approach
Multitargeted agents approach with Renal Carcinoma (RCC), Breast cancer and NSCLC


Multitargeted agents affecting with Renal Carcinoma (RCC), Breast cancer and NSCLC

VEGF-Rs and EGFR, PDGF-Rs etc.

  • ZD6474 (VEGF-R2 + EGFR + RET)

  • AE778 (VEGF-R2 + EGFR)

  • SU11248 (VEGFRs + PDGF-Rs+ c-Kit)

  • Sorafenib (VEGFRs + PDGF-Rs + MAPK + Erk + c-Kit)

  • PTK787 (VEGFRs + PDGF-Rs)


ZD6474 inhibits KDR and EGFR with Renal Carcinoma (RCC), Breast cancer and NSCLC

TGF

ZD6474

EGFR

KDR

Endothelial cells

RET

Cancer cells

VEGF

Angiogenesis

Tortora & Ciardiello 2003

Carlomagno et al, Cancer Res. 2002

Ciardiello et al., Clin Cancer Res. 2003

Ciardiello et al., Clin Cancer Res. 2005

Damiano et al., Clin Cancer Res 2005

Cell Proliferation


1.00 with Renal Carcinoma (RCC), Breast cancer and NSCLC

Median progression-free survival:

Placebo + docetaxel = 12.0 weeks

ZD6474 100 mg + docetaxel = 18.7 weeks

ZD6474 300 mg + docetaxel = 17.0 weeks

0.75

Probability of remaining progression-free

0.50

0.25

0

0

50

100

150

200

250

300

350

400

Progression-free survival (days)

Randomized Phase II trial of ZD6474 plus docetaxel in patients with NSCLC. Primary endpoint : PFS

Objective responses

Placebo+D = 12%

ZD 100 +D = 26%

ZD 300 +D = 18%

DATI ANCORA IMMATURI PER OS


Targeting vegf and egfr aee788 phase i trial
Targeting VEGF and EGFR: AEE788 with Renal Carcinoma (RCC), Breast cancer and NSCLCPhase I trial

  • dose-dependent inhibition of EGFR signalling in skin and tumour observed

  • most common adverse events were diarrhea (67%), fatigue/asthenia (51%), anorexia (49%), rash (43%), nausea (42%) and vomiting (28%)

  • DLT (diarrhea) dose levels defined at 500 and 550 mg

2Baselga J, et al. J Clin Oncol 2005;23(June 1 Suppl.):198s (Abstract 3028)

3Martinelli E, et al. J Clin Oncol 2005;23(June 1 Suppl.):201s (Abstract 3039)


The endothelial cell-pericyte network of signals with Renal Carcinoma (RCC), Breast cancer and NSCLC

  • Pericytes protect endothelial cells from apoptosis

  • and overexpress PDGF-R

  • PDGF-R is overexpressed in many tumors

  • PDGF-R and VEGF cooperate

Nature Review Cancer


SU11248 is active in different tumors with Renal Carcinoma (RCC), Breast cancer and NSCLC

  • Activity observed in leukemia

  • Active in sarcomas

  • Active in GIST (including those resistant to imatinib)


SU11248 in mRCC with Renal Carcinoma (RCC), Breast cancer and NSCLCActivity Versus Other Second-Line Agents

*Escudier et al. J Clin Oncol. 1999;17:2039-2043; †Yang et al. N Engl J Med. 2003;349:427-434;‡Motzer et al. J Clin Oncol. 2004; 22:454-463.


Phase II study of SU11248 in MBC with Renal Carcinoma (RCC), Breast cancer and NSCLC

  • 6 weeks cycle (50 mg/day for 28 d. and 2 weeks rest).

  • 64 pts enrolled (80% HER-2 negative/unknown). The majority with multiple visceral sites. Heavily pretreated (several previous CT regimens, also in adjuvant setting).

  • Asthenia and diarrhea major grade 2 toxicities. 40% grade 3 neutropenia.

  • 51 evaluable for responses. PR: 7 (14%); SD > 6 mo: 1 (2%). Study is ongoing.

  • No obvious correlation between response and ER or HER-2 status.

Miller et al., ASCO 2005


PTK/ZK: A multi-VEGF receptor tyrosine kinase inhibitor with Renal Carcinoma (RCC), Breast cancer and NSCLC

PTK787/ZK 222584

(Vatalanib)

Formula: C24H21N4Cl

MW = 346.82

  • Complete inhibitor of the VEGF receptor tyrosine kinasesVEGFR1(FLT-1), VEGFR2 (KDR) and VEGFR3 (FLT-4). It also inhibits PDGF-R.

  • Well tolerated up to 1250 mg/day (phase III dose, used up to 15 mo)

  • Rapidly absorbed (1 to 2.5 hours), T1/2: 3-6 hrs

  • Renal metabolism


ONGOING AND PLANNED PHASE III with Renal Carcinoma (RCC), Breast cancer and NSCLCCONFIRM STUDIES

Chemonaive CRC

FOLFOX + PTK

Over 700 pts treated up to date

in combination with CT

CPT-11/FU resistant CRC

FOLFOX + PTK


Bay 43 9006 sorafenib

Cl with Renal Carcinoma (RCC), Breast cancer and NSCLC

O

O

N

F

C

N

H

N

H

3

C

H

3

O

N

H

BAY 43-9006 (Sorafenib)

  • Bisaryl urea, multiple targeted inhibitor.

  • Inhibits B-Raf-1 kinase (including the mutated form) with IC50 of 6 nM, MAPK, ERK.

  • Inhibits also endothelial cells and VEGFR2, VEGFR-3,FLT-3, PDGFR, c-Kit.

  • Raf is probably important in endothelial cells and double targeting (Raf and VEGFR-2) may be critical.


ad